News related to Taxol (Paclitaxel) and/or conditions it is approved for
Weekly Doses of Taxol Prolonged Lives of Breast Cancer Patients
Source: MedicineNet cyclophosphamide Specialty [2008.04.17]
Title: Weekly Doses of Taxol Prolonged Lives of Breast Cancer Patients
Category: Health News
Created: 4/17/2008 2:00:00 AM
Last Editorial Review: 4/17/2008
CTS: Gefitinib Superior to Chemotherapy Among Asians with Lung Cancer
Source: MedPage Today Hematology/Oncology [2008.11.17]
CHICAGO (MedPage Today) -- For carefully selected Asian patients with non-small-cell lung cancer, the tyrosine kinase inhibitor gefitinib (Iressa) significantly improved progression-free survival compared with the standard carboplatin (Paraplatin) and paclitaxel (Taxol), researches reported here.
Paclitaxel Plus Chemo Improves Outcomes in Early Breast Cancer
Source: MedicineNet cyclophosphamide Specialty [2008.05.28]
Title: Paclitaxel Plus Chemo Improves Outcomes in Early Breast Cancer
Category: Health News
Created: 5/28/2008 2:00:00 AM
Last Editorial Review: 5/28/2008
Gemcitabine Plus Paclitaxel Increases Survival in Metastatic Breast Cancer
Source: Medscape Pharmacotherapy Headlines [2004.06.10]
Time to progression is also significantly better than with paclitaxel alone, and the combination does not increase toxicity.
Medscape Medical News
Study First To Combine 2 Chemotherapies And 2 Targeted Therapies
Source: Lung Cancer News From Medical News Today [2008.11.14]
The four drug-combination of carboplatin and paclitaxel, with the targeted therapies bevacizumab (Avastin) and cetuximab (Erbitux), is safe and may improve survival for patients with advanced lung cancer, according to a cooperative group study led by The University of Texas M. D. Anderson Cancer Center.
Phase 2 Study Of IMC-1121B In First-Line Treatment Of Advanced Non-Small Cell Lung Cancer Starts Patient Enrollment
Source: Lung Cancer News From Medical News Today [2008.11.13]
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed Phase 2 clinical trial of IMC-1121B in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC) has opened for patient enrollment. IMC-1121B is ImClone's proprietary fully human, IgG1 anti-vascular growth factor receptor-2 (VEGFR-2) monoclonal antibody.
|
